BioSpace2d
Novo’s CagriSema Blunder Underscores Sky-High Investor Expectations for Weight Loss Drugs
Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 ...
BioSpace2d
Phase III MASH Miss Sends Galectin Stock Tumbling
Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...
BioSpace2d
GSK Posts Mixed Survival Data for Jemperli/Zejula Combo in First-Line Ovarian Cancer
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...
BioSpace2d
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a ...
BioSpace2d
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...
BioSpace2d
Ionis’ Tryngolza Becomes First FDA-Approved Therapy for Familial Chylomicronemia Syndrome
Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that ...
BioSpace2d
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for ...
BioSpace2d
Boston Institute of Biotechnology, LLC with BiBo Pharma Announce Groundbreaking Expansion to Revolutionize Global Biologics Production Capacity
BOSTON, Dec. 19, 2024 /PRNewswire/ --Boston Institute of Biotechnology, LLC (BIB), along with its sister company BiBo Pharma, pioneering Contract Development and Manufacturing Organizations (CDMOs) ...
BioSpace2d
Presse release: Jean-Paul Kress to join Sanofi’s Board of Directors
Paris, December 19, 2024. Sanofi’s Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp who has decided to leave the ...
BioSpace2d
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH ® (palopegteriparatide; developed as TransCon PTH) is now commercially ...
BioSpace2d
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk ® Hereditary Cancer Test ...
BioSpace2d
OraSure Technologies Acquires Sherlock Biosciences
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today ...